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Abstract
Although congenital cytomegalovirus (cCMV) is the leading non-genetic cause of childhood hearing loss in the United
States, neither targeted nor universal screening protocols have been well established to identify cCMV in newborns.
Moreover, until cCMV testing is universal, clinical protocols need to account for the complexities of individualized care in
partnership with interprofessional care teams. This work addressed an immediate clinical practice need to identify cCMV
with subsequent hearing monitoring of babies who test positive for cCMV. This effort focused on three primary objectives
to: (a) define interprofessional, team-based approach to facilitate care pathways; (b) develop a clinical workflow for all
babies who refer on inpatient hearing screening to be tested for cCMV by 21 days of age; and (c) develop a hearing
monitoring plan for all babies who test positive for cCMV. The article describes the development and integration of our
interprofessional, team-based approach to institute cCMV testing by 21 days of age on all babies who refer. Description
of the inpatient newborn hearing screening and subsequent monitoring is also included. Our observed referral rate was
lower than predicted (2.7%) from existing literature with only one positive cCMV outcome noted in the two-year span. This
study demonstrates the feasibility of a hearing-targeted cCMV testing paradigm in our clinic practice.
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Babies born with congenital cytomegalovirus (cCMV)
infection may present with immediate and long-term health
problems, one of which is hearing loss detectable at birth
or developing later in childhood (reviewed by Goderis et
al., 2014 and WHO, 2021). cCMV is common in the United
States presenting in 1 out of 200 babies (~0.6%; Centers
for Disease Control and Prevention [CDC], 2020; Fowler

et al., 2018). Of babies infected with cCMV, about 10% are
symptomatic at birth, 10 to 15% are asymptomatic at birth
yet develop hearing loss or other neurological impairments
at a later onset, and the remaining majority (75–80%) are
asymptomatic (Boppana et al., 2013; CDC, 2020; Goderis
et al., 2014; Kenneson & Cannon, 2007). Symptomatic
babies may exhibit multiple system conditions because
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of cCMV which may include thrombocytopenia,
hyperbilirubinemia, or central nervous system involvement
such as microcephaly with significant neonatal morbidity
and mortality (e.g., Rawlinson et al., 2017).
Sensorineural hearing loss is the most common diagnosis
for a baby infected with cCMV, whether symptomatic or
asymptomatic for other systems’ involvement (Naing et
al., 2016). Estimates suggest that cCMV accounts for 25
to 40% of total hearing loss in children (Goderis et al.,
2014). Sensorineural hearing loss occurs in approximately
20 to 40% of babies with multisystem involvement and
is a single system finding in 5 to 10% of cCMV cases
(Dollard et al., 2007; Fowler & Boppana, 2006, 2018;
Goderis et al., 2014; Rawlinson et al., 2017). Although this
is counter-intuitive, hearing loss has not been included
in the definition of symptomatic cCMV; asymptomatic
cCMV is a distinct category and can include hearing loss
(Petersen et al., 2020; Rawlinson et al., 2017). Therefore,
asymptomatic cCMV cases may present with hearing loss
as the only clinical finding (Fowler & Boppana, 2006, 2018;
Goderis et al., 2014).
Universal newborn hearing screening successfully detects
congenital hearing impairment at birth; however, concerns
for delayed onset or progressive hearing loss require longer
term monitoring (Joint Committee on Infant Hearing [JCIH],
2019; World Health Organization [WHO], 2021). At this time,
screening for cCMV is not performed for all newborns. The
debate over universal newborn cCMV screening versus
targeted screening is ongoing. However, growing evidence
and clinical practice goals of universal or extended neonatal
cCMV screening aimed at detection of cCMV at the earliest
are progressing (e.g., Krishna et al., 2020). Hearingtargeted screening for cCMV can be one step in advancing
toward the goal of universal cCMV testing for all newborns
and for promoting earlier detection of delayed onset or
progressive hearing loss (e.g., JCIH, 2019). That said,
such targeted approaches are imperfect as they are biased
toward missing cCMV positive cases with passed newborn
hearing screening results (see review of considerations by
Haller et al., 2020 and Krishna et al., 2020). Evidence in the
realm of early detection has resulted in recommendations
for inclusion of cCMV testing if sensorineural hearing loss
is detected as a result of newborn hearing screening (Choi
et al., 2009; Haller et al., 2020; Korver et al., 2017; Park
& Shoup, 2018). Hearing-targeted cCMV screening and
outcomes data (Diener et al., 2017; Fowler et al., 2017)
support legislative efforts to mandate cCMV testing based
on newborn hearing screening outcomes and potentially
beyond (National CMV Foundation, 2021). Moreover,
accounting for delayed-onset or progressive hearing loss
over the first years of life is of growing importance (e.g.,
Cannon et al., 2014; WHO, 2021).
Early cCMV testing is critical as this is the only means to
differentiate between congenital and postnatally acquired
infection. Detection of cCMV can be made within the
first weeks of life by detecting the virus from a culture or
polymerase chain reaction (PCR) of body fluids such as
urine or saliva (Boppanna et al., 2011; CDC, 2020). This

is most helpful for timely detection of asymptomatic cCMV
cases as positive cCMV tests within the first 14 to 21 days
of life help distinguish congenital from acquired CMV
(Revello & Gerna, 2002). Testing of the newborn screening
card dried blood spots may permit later diagnosis of
cCMV as such samples are collected in the desired
timeframe and may retrospectively help to distinguish
between congenital and acquired CMV (e.g., Choi et
al., 2009). Only congenital CMV causes hearing loss
or symptomatic disease; whereas, postnatally acquired
infections are not associated with disease (e.g., Boppana
et al., 2010; Choi et al., 2009; Meyer et al., 2017). In
the case of cCMV, newborns who are symptomatic or
asymptomatic will continue to shed and transmit the
virus through bodily fluids for 18 to 30 months (Pati et al.,
2016). This knowledge is critical for treatment planning
and consideration for antiviral therapy (Rawlinson et
al., 2017). Timely diagnosis leads to timely intervention;
specifically, all treatments began before 30 days of life in
initial trials validated antiviral medications (Kimberlin et al.,
2003, 2015; Rawlinson et al., 2017). Similarly, continued
monitoring for later onset of hearing loss in children who
were positive for cCMV can help with earlier diagnosis of
hearing loss, facilitate fitting of assistive hearing devices,
and support earlier access to speech and language
interventions (Boppana & Fowler, 2017; JCIH, 2019;
Kennedy et al., 2006).
The work presented here developed from the immediate
clinical practice need for Mayo Clinic Rochester and
Mayo Clinic Health System (outreach clinical sites
throughout Minnesota and Wisconsin) to converge
on clinical practice approaches to identify cCMV and
subsequently monitor babies who tested positive for
cCMV in the newborn population. This effort focused on
three primary study objectives that we developed (based
on baseline program review from 2015–2017), deployed
(January 2018), and reviewed over a two-year span
(2018–2019). This article describes the development and
integration of our interprofessional, team-based approach
to quality improvement efforts to conduct cCMV testing
by 21 days of age on all babies who refer (in at least
one ear) on inpatient newborn hearing screening. It also
describes the follow up process developed for ongoing
hearing monitoring of this population. Specific project
objectives include: (a) define interprofessional, teambased approach to facilitate care pathways; (b) develop a
quality improvement strategy where all babies who refer
on inpatient hearing screening get cCMV testing by 21
days of age; and (c) develop a hearing monitoring plan for
all babies who test positive for cCMV, keeping in mind that
some may be found to have normal hearing.
Method
Participants
All newborns at Mayo Clinic undergo newborn hearing
screening according to Minnesota state guidelines
(Minnesota Department of Health [MDH], 2021). The
population at Mayo Clinic includes newborns who stay on
a postpartum/newborn nursery unit (well child) with their
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mothers and patients who stay on a Level III neonatal
intensive care unit (NICU) and a Level IV NICU. Mayo
Clinic Rochester has been conducting inpatient hearing
screening on all newborns since 1999. The practice
screens approximately 2335 newborns per year (5-year
average) on the newborn nursery unit and two NICUs.
Overview of the birth cohort focus for this evaluation preand post-screening for cCMV is detailed in Table 1.

Figure 1
Overview of Two Step Protocol in the Newborn Hearing
Screening Workflow

Table 1
Overview of Birth Cohort from the Newborn Nursery
Population Defined as Number of Patients Screened
Mayo Clinic
Rochester, MN
Newborn Nursery Population
Year

2015

2016

2017

2018

2019

Birth Cohort

1899

1839

1903

1882

1921

Pass

1850

1774

1800

1747

1803

Refer/
Fail

49

65

103

135

118

Hearing
Screenings

Note. Screening results of pass in both ears and the target
for this investigation of referred in one or both ears also
depicted for 2015 to 2019. The thick vertical line delineates
baseline (2015–2017) prior to implementation of the
congenital cytomegalovirus (cCMV) screening triggered by
refer/fail on newborn hearing screening (active since 2018).
Newborn Hearing Screening Protocol
Audiology staff, including audiology assistants and
audiologists, conduct the newborn hearing screenings
at Mayo Clinic Rochester. On the newborn nursery unit,
screening is conducted using a two-step method (See
Figure 1). Otoacoustic emissions (OAE) are used as a first
level screening. Screening is considered complete if there
is a passing result for both ears using OAE. Automated
auditory brainstem response (AABR) is conducted if there
is a refer result on the first OAE screening. Screening is
considered complete if there is a passing result for both
ears using the AABR technology. In the NICU settings,
screening is conducted using only the AABR technology.
Screening is considered complete if there is a passing
result for both ears. A maximum of two screening attempts
are conducted during the inpatient stay. For patients on all
units, risk factors for early childhood hearing loss (JCIH,
2007; 2019) are reviewed and documented.
Location

The focus of this evaluation is on the newborn nursery
unit, where screening is conducted by one audiologist
coordinator, seven audiology assistants, and two
audiology doctoral student externs. The location of
screening varies and is prioritized for family-centered
care. Screening is initially offered to be conducted at the
mother’s bedside and with parent(s) present whenever
possible. This aspect of the program lends a familycentered care emphasis and is the most common location
for screening in our practice.

Note. The first level of screening (Step 1) uses otoacoustic
emission (OAE) technology and the second step uses
automated auditory brainstem response (AABR) technology.
Refer/Fail outcomes prompt next level of screening.
Timing
Newborns on the nursery unit are typically seen for hearing
screening on the first full day of life. Screening is typically
completed late morning or early afternoon on the first
day, so the patients may be in the range of 12 to 36 hours
old when screening is completed. In either of the NICU
settings, screening is conducted as the patient is getting
closer to dismissal (typically within 1–2 weeks of dismissal).
Equipment

Screening is conducted using the Otodynamics Otoport
TE+DP OAE+AABR equipment in all units. This is a
handheld piece of equipment that plugs in to a computer
kept on a cart and is transported to the newborn’s location
for screening. This allows the screener to be mobile and
permits timely access to the electronic health record and
reporting applications for maximum efficiency in the clinical
practice. The handheld equipment can be transported into
the mother’s room without the full cart for a less obtrusive
experience for the family and to maximize bedside
screening opportunities.
AABR and OAE screening equipment settings are consistent
across all units. Of note, the equipment that was in use
from 2015 to 2018 included the ALGO 5 Newborn Hearing
Screener for AABR and Otodynamics Echoport 292 for
transient otoacoustic emissions (TEOAE). The Otodynamics
Otoport TE+DP OAE+AABR was in use from 2018 to 2019.
Data Management

Results and risk factors are entered into an internally
created database called the Early Hearing Detection and
Intervention (EHDI) application (developed at Mayo Clinic
Rochester, 2009). This application was designed to track
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inpatient and outpatient screening as well as follow up
results for newborn hearing screening. The audiologist
or audiology assistant creates a note in the electronic
health record as well. Results are also sent electronically
to the MDH. Data is exported from the handheld units to
minimize errors due to manual entry. A program coordinator
maintains the internal EHDI database, oversees review of
risk factors for early childhood hearing loss, monitors follow
up, and directs the ongoing quality improvement initiatives.
Patient Education

Newborn hearing screening results are delivered by
the examining audiologist or audiology assistant to
the parent(s) at the time of the screening. Results are
delivered verbally and in writing as standard practice. In
person, tablet, or telephone language interpreters are
used when appropriate. Two patient education brochures
are offered to families. The first brochure describes the
screening process and explains why hearing screening
is being done for a newborn. This brochure also has a
checkbox for a pass or refer result so that the family has a
record of the results before hospital dismissal. The family
also has access to the screening results in the electronic
health record patient portal. The second brochure has a
list of typical developmental milestones for speech and
language abilities up to age 5 years and is intended as a
reference for parents to use while monitoring their child’s
speech and language development.
When a baby is leaving the hospital with a refer result, the
person who conducts the hearing screening documents this
in the internally created EHDI database and in the note in the

electronic health record and sends a message (also through
the electronic health record) to the audiology scheduling
team. The scheduling team contacts the family directly to
schedule an outpatient rescreen appointment in 1 to 2 weeks.
Congenital Cytomegalovirus (cCMV) Testing Protocol
For this evaluation, patients leaving the hospital with a
refer result on newborn hearing screening in one or both
ears were offered cCMV testing. This included patients
with a refer after one attempt if a second attempt is not
possible before discharge. cCMV testing was performed
as urine PCR (polymerase chain reaction) or saliva swab
depending on what was feasible at the time of collection
prior to hospital dismissal (e.g., Rawlinson et al., 2017;
JCIH, 2019). Refer to Figure 2 for workflow of cCMV
testing prompted by hearing screening outcome. This was
implemented in January 2018 and this article reviews the
outcomes over a two-year period (2018 to the end of 2019).
In addition to the previously described process for newborn
hearing screening above, the person who conducts the
hearing screening also notifies the nurse caring for the
patient that the patient will be leaving with a refer result
(one ear or two) for hearing screening. This prompts the
nurse to activate the cCMV collection order set in the
electronic health record (and workflow in Figure 2). The
nurse informs the family that cCMV testing is completed
whenever a patient is leaving the hospital with a refer
result on newborn hearing screening. The nurse collects
a sample for this test (as appropriate). Urine is the
preferred specimen, but saliva (buccal swab) is considered
appropriate if urine cannot be collected in a timely manner.

Figure 2
Overview of cCMV Testing Workflow for Newborns Triggered by Refer/Fail On Newborn Hearing Screening by 21 Days of Life
Refer on newborn
hearing screening in one
or both ears

cCMV testing order
activated
(urine cCMV PCR; if not
urine order saliva cCMV
PCR)

Test NEGATIVE

Notify Family
(Screening Complete)

Test POSITIVE

Prompts referral to
Pediatric Infectious
Disease Consultation

Prompts referral for
Audiologic Evaluation and
Monitoring

Test not obtained

Notify primary care to
activate order
(urine cCMV PCR; if no
urine order saliva cCMV
PCR)

Note. Congenital cytomegalovirus(cCMV) testing ordered and sample collected prior to hospital dismissal. PCR =
polymerase chain reaction.
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PCR testing is completed at the Mayo Clinic Laboratories
with results reported in the electronic health record in 1
to 2 days. A PCR positive result triggers an immediate
referral to the Pediatric Infectious Diseases Outpatient
Clinic or a Pediatric Infectious Diseases inpatient
consultation if the patient remains in the hospital. The
Pediatric Infectious Disease provider then initiates an
evaluation for other evidence of all organ involvement
while awaiting final audiology results. If the evaluation
indicates the infant has symptomatic cCMV, treatment is
discussed with the parents or guardian.
Patient Education Development

Figure 3
Overview of Interprofessional Collaborative Care Team
Approach

Interprofessional Collaborative
Care/Team-based Approach
Audiology
Genetics
Pediatric Infectious Disease
Pediatric Otolaryngology

cCMV testing results are delivered to the parent(s) by the
managing primary care team. In a coordinated effort by the
interprofessional care team, a patient education piece was
created to assist the primary care providers in educating
their patients and their families about cCMV and its
connection to hearing loss. The piece, entitled “Congenital
Cytomegalovirus (cCMV),” is a 12-page brochure created
by Mayo Clinic Health Education and Content Services led
by Audiology in collaboration with colleagues in Pediatric
Infectious Disease, Genetics, Pediatric Otolaryngology,
and Primary Care. Topics include a description of cCMV
and causes, the relationship between cCMV and hearing
loss, an overview of testing for cCMV, as well as treatment
and prevention of cCMV.
Results
Interprofessional Collaborative Care Team Approach
An interprofessional collaborative care team was
established to address this clinical practice need with
the goal of initiating cCMV testing prior to dismissal
from the hospital on all babies in the newborn nursery
with a refer result on their newborn hearing screening.
Interprofessional collaborative practice occurs when
multiple health workers from different professions provide
comprehensive services by working with patients,
caregivers, and communities to deliver the highest quality
of care across settings (WHO, 2010). The Interprofessional
Education Collaborative (IPEC, 2016) further defined
several competencies for teams of professionals working
toward this type of practice. These include a climate
of mutual respect and shared values, clearly defined
roles and responsibilities, responsive and responsible
communications with patients and their families as well
as other professionals, and application of the principles of
effective team dynamics.
For the purposes of this project, the interprofessional
collaborative care team (See Figure 3) included
representatives from the following specialty areas:
Audiology, Genetics, Pediatric Infectious Disease,
Pediatric Otolaryngology, Nursing, Primary Care (Family
Medicine; Community Pediatrics), Neonatology, Hospital
Desk Operations, Patient Appointment Services, and
Patient Education. Representatives from the various
groups worked together in smaller groups to accomplish
portions of the project. For instance, pediatric expert
representatives from audiology, infectious disease,
genetics, pediatrics, and otolaryngology collaborated to

Nursing
Primary Care
Neonatology
Hospital Desk Operations
Patient Appointment Services
Patient Education

Note. There are many other collaborating providers;
however, this reflects the initial launch team described in
this study.
create a patient education piece (described in Patient
Education Development) designed to support primary care
providers when discussing the concept of cCMV testing
with parents.
Defined Care Team Pathway for Audiology (Outpatient)
To facilitate the goal that all babies who do not pass
hearing screening will undergo cCMV testing by 21 days of
age, care pathways within the inpatient setting (see Figure
2 above) as well as in the outpatient setting (Figure 4)
were defined as part of this project. Our objective was to
develop a follow up plan for all babies who test positive for
cCMV, keeping in mind that some may be found to have
normal hearing. Figure 4 provides an overview of the care
team coordination and plan for additional monitoring and
management.
With implementation of a cCMV testing program into the
clinical practice, an audiological monitoring pathway and
protocol needed to be defined to account for individuals
testing positive for cCMV and based on hearing status.
The testing within this protocol will vary slightly depending
on the patient population and individualized patient needs.
Primary populations following this protocol will be patients
who test positive for cCMV and who (a) Refer, miss, or
refuse on newborn hearing screening and subsequently
have confirmed sensorineural hearing loss, conductive
hearing loss, or mixed hearing loss; and (b) Refer, miss,
or refuse on newborn hearing screening and subsequently
have confirmed hearing sensitivity within normal limits.
An interprofessional collaborative care team-based
approach is critical when serving patients with cCMV with
or without hearing loss. Clearly defined clinical pathways
for the identification and management of cCMV can
facilitate early intervention options. The care team needed
for an effective monitoring program is one in which team
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Figure 4
Care Team Coordination and Management Plan for Individuals Testing Positive for cCMV

Note. Care team coordination and management plan defined prospectively to define care pathway for individuals testing
positive for congenital cytomegalovirus (cCMV) with specific focus on differences between care plan for individuals with
hearing loss versus those with typical hearing. Please note this is an overview rather than exhaustive care plan in which
individualized patient needs are also addressed. ABR = auditory brainstem response; OAE = otoacoustic emissions.
*If initiated, valganciclovir treatment is for 6 months unless adverse effects prevent the full course of treatment.
members from different professions work in collaboration
for timely identification, monitoring, and intervention as
appropriate. Four of the professions (see Figure 3) are
described in detail below for an overview of this approach.
Audiology
For Audiology, when babies refer on inpatient newborn
hearing screening (refer to Figure 1), patients are
immediately scheduled for outpatient rescreen within 1 to 2
weeks. If there is a refer result on the outpatient rescreen
of hearing, then patients proceed with a scheduled
diagnostic audiologic evaluation with an audiologist as
soon as possible (typically, within 1–2 weeks). Audiologic
evaluation may include frequency-specific threshold
auditory brainstem response (ABR), auditory steady state
response (ASSR), otoacoustic emissions (may include
TEOAEs and distortion product otoacoustic emissions
[DPOAEs]), and immittance measurements (including

tympanometry and acoustic reflex testing). Evaluation and
confirmation of hearing status may occur over multiple
visits.
When audiologic evaluation leads to diagnosis of hearing
loss, the next steps (refer to Figure 4; AUD section) are
to monitor every 3 months until age 1, every 6 months
until age 3, and annually until age 19. When audiologic
evaluation leads to diagnosis of hearing sensitivity within
normal limits, the next steps are to monitor every 3 months
until age 1, every 6 months until age 3, and annually until
age 19. Although the timing of the monitoring visits is
the same for the two populations, the specific monitoring
tools are different. The testing for the population with a
diagnosis of hearing sensitivity within normal limits will
focus on and prioritize objective screenings, such as OAE
and tympanometry unless change in hearing is more highly
suspect (modified from Figure 2 in Foulon et al., 2015).
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Pediatric Otolaryngology

Pediatric Infectious Disease

For Pediatric Otolaryngology, there is a close partnership
with Audiology when audiologic evaluation leads to
diagnosis of hearing loss (refer to Figure 4; ORL section).
Additional medical evaluation of hearing loss may include
detailed review of medical history, brain imaging for
medical evaluation to help predict neurodevelopmental
outcomes, referrals for speech and language development
evaluation, et cetera. Efforts are led by otolaryngology for
medical management of conductive hearing loss, which
may include partnership with primary care teams. Pediatric
Otolaryngology will often serve as the lead for early
medical clearance for amplification or rehabilitation trials
as well as the entry point for referrals for consideration
of early cochlear implantation as appropriate. Specific
to cCMV positive cases, additional management may
include brain imaging for medical evaluation to help predict
neurodevelopmental outcomes, early medical clearance for
amplification and (re)habilitation trials, and consideration of
early cochlear implantation as appropriate.

For Pediatric Infectious Disease, evaluation for evidence of
symptomatic cCMV disease and treatment for symptomatic
infants are the key considerations and components
to manage (refer to Figure 4; IFD section). Next steps
following a cCMV positive test result include physical
examination; lab studies such as Complete Blood Count
(CBC) with differential, liver function tests (LFT), creatinine;
and brain imaging (preferably MRI). Developmental
evaluation should begin at the first year for children with
symptomatic cCMV on a case by case basis. Practitioners
will also want to review audiology in at least 6 month
intervals through age 3 years and align them with the
prospective monitoring (defined in Figure 4; AUD section).

Genetics

For genetics, the identification of cCMV positive individuals
in combination with hearing status helps guide next steps
for the care plan (refer to Figure 4; CGE section). Additional
work-up may include: utilization of evaluations obtained
from care team, referral to pediatric ophthalmology (and
other specialties as needed), and detailed family history
and genetic counseling as appropriate. Targeted genetic
testing is warranted, particularly, if there is a family history
of hearing loss suggesting that there may be coincident
cCMV as well as a genetic condition. Negative targeted
genetic testing in the face of positive cCMV testing
provides supporting evidence that cCMV alone would be
the underlying cause of hearing loss.

Treatment of symptomatic cCMV disease is led by Pediatric
Infectious Disease in partnership with the broader care
team. Specific to cCMV treatment, infants are examined
at least monthly with dose adjustments of valganciclovir
based on weight gain and monitoring for adverse effects of
oral valganciclovir treatment including CBC with differential,
liver function tests, and creatinine. Monitoring of hearing
helps support the treatment which may be conducted
through age 19 years based on need (as described above).
Hearing-Targeted cCMV Testing
Table 2 provides an overview of the numbers of newborns
who did not pass hearing screening in both ears and cCMV
testing. cCMV testing was implemented in January 2018 and
here we review outcomes over a two-year period (2018 to
the end of 2019) with baseline data reviewed from January
2015 to December 2017. During this time, 1882 newborns
were screened in 2018 and 1920 screened in 2019 (refer to
Table 1). The referral rate from newborn hearing screening
is displayed by year in Table 2 with the 5-year average of
5% of newborns screened referred for hearing. Of those

Table 2
Overview of cCMV Testing Results from the Newborn Nursery Population

Year

Mayo Clinic
Rochester, MN
Newborn Nursery Population
2015

2016

2017

2018

2019

2.58%

3.53%

5.41%

7.17%

6.14%

49

65

103

135

118

1

2

3

4

3

112

115

Test Positive

0

1

Test Negative

112

114

Refer Rate (refer total/ birth

Hearing
cohort in %)
Screenings
Refer/Fail

Hypothesized
Test Positive

cCMV
Testing

Actual
Test Complete

Note. Screening results of pass in both ears and the target for this investigation of referred in one or both ears also

depicted for 2015 to 2019. The thick vertical line delineates baseline (2015–2017) prior to implementation of the congenital
cytomegalovirus (cCMV) testing triggered by refer/fail on newborn hearing screening (active since 2018). The gray shading
denotes hypothesized values or intentionally blank cells prior to the initiation of cCMV testing.
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that refer on hearing screening, we anticipated to find about
2 to 3 babies per year from our birth cohort that would
refer for our monitoring protocol based on our program
data from 2015 to 2017 (see Table 2). This referral rate for
cCMV was predicted based on prior evaluations at similar
institutions (2.7% refer rate; Choi et al., 2009). Based on
these predictions, we planned a monitoring protocol that we
expected would be manageable within the framework of our
existing clinical practice (see Figure 2).
Most of those individuals that referred on newborn
hearing screening were tested for cCMV (83.0% in 2018
and 97.5% in 2019). No newborns were identified via
targeted testing for cCMV in 2018 and only one patient
was identified in 2019. This is less than our hypothesized
cCMV refer rate of 4 in 2018 and 3 in 2019 (Table 2).
Discussion
Congenital cytomegalovirus (cCMV) is a cause of
neurodevelopmental delay in children and a common
cause of nonhereditary sensorineural hearing loss (CDC,
2020; Goderis et al., 2014; Kenneson & Cannon, 2007;
Kimberlin et al., 2015). Although prevalent, cCMV has
gone largely undetected because most babies that are
cCMV positive are asymptomatic. The early detection of
hearing loss may help identify cCMV as well as promote
early intervention for hearing loss. In our practice,
exploration of hearing-targeted screening for cCMV was an
initial step in advancing toward the goal of universal cCMV
testing for all newborns and for promoting earlier detection
of delayed onset or progressive hearing loss. In this article,
we described our efforts focused on defining the care
pathway for the identification and audiologic monitoring of
individuals who refer on newborn hearing screening and
subsequently test positive for cCMV by 21 days of age
in the newborn nursery population. Three primary study
objectives were to (a) define the interprofessional, teambased approach to facilitate care pathways; (b) develop
the clinical workflow for all babies who refer on inpatient
hearing screening to get cCMV testing by 21 days of age;
and (c) develop a hearing monitoring plan for all babies
who test positive for cCMV.
Family-Centered Interprofessional Collaborative Care
The first objective was to establish an interprofessional
collaborative care team (Figure 3) to address the
immediate clinical practice need with the goal of initiating
cCMV testing prior to dismissal from the hospital on
all babies with a refer (in one or both ears) on their
newborn hearing screening. As described above, many
considerations and care team components were explored.
Future considerations around defining pathways for
inpatient versus outpatient screening and monitoring,
internal versus external patient entry options, as well
as hearing loss risk (based on degree and progression
concern) will be explored. Moreover, longer term
monitoring aspects warrant continued exploration given the
small population and need for longer-term data (beyond
the age of 19 years as described above).
Throughout the work on this project, the interprofessional
care team also recognized that the child and their

family are arguably the most important members of the
overall team caring for the child. Family-centered care
has always been a focus of the Mayo Clinic newborn
hearing screening program. From the decision to offer
to screen in the mother’s room as well as with parent(s)
present to the scheduling of outpatient appointments
before dismissal whenever possible, every decision
is made with the experience of each family in mind.
Family-centered care means working toward a respectful
partnership between the family and the professionals. It
also focuses on the principles of honoring and respecting
the strengths, cultures, and expertise that families and
professionals each bring to the health care interaction
(Family Voices, 2021; Kuo et al., 2012; American Academy
of Pediatrics, 2012). The principles of family-centered care
were considered during all of the work on this project.
It is well documented in the literature that parent and
medical professional knowledge about cCMV is quite
limited. Others are working on increasing awareness of
cCMV among pregnant women, those who may become
pregnant, and medical professionals (see resources in the
National CMV Foundation, 2021; Park et al., 2020). During
our project, the creation of the patient education brochure
was part of our team’s efforts to increase awareness
among providers and parents. One way the team could
enhance these efforts in the future is to incorporate patient
experience feedback and refinement of the materials.
Linking Newborn Hearing Screening and cCMV Testing
Development of a care pathway for a targeted approach
to cCMV screening was the primary focus and one of
the key objectives of this collaboration. Based on review
of available literature, we anticipated that the newborn
hearing screening program would identify more individuals
with cCMV using this targeted approach to testing based
on hearing screening outcomes. Specifically, we predicted
a referral rate by year based on prior evaluation at a similar
institution (e.g., Choi et al., 2009) which estimated about
2.7%. Our predicted estimates for the newborn nursery
population is displayed by year in Table 2. As can be seen
from two years of this targeted approach, we anticipated
identification of approximately seven patients with cCMV.
Instead, we identified only one newborn during the two
years with the targeted screening (equating to a referral
rate of 0.85% in 2019 and 0% in 2018). Outcomes from
this study demonstrate the feasibility of a hearing-targeted
cCMV testing paradigm in our clinic and establishes the
framework for expanded neonatal cCMV screening or
universal screening for cCMV in the future. This aligns with
prior published efforts (Diener et al., 2017; Fowler et al.,
2017; Haller et al., 2020; Krishna et al., 2020).
It is expected that more cCMV positive cases would be
identified if a universal approach to cCMV testing were
implemented. Because hearing loss that is secondary
to cCMV is often progressive or later-onset in nature, a
universal approach to cCMV testing and monitoring would
help to identify those patients who receive a pass result on
their newborn hearing screening and should be monitored
for hearing changes (e.g., Haller et al., 2020). A universal
cCMV testing approach would further the critical goals
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of timely detection and hearing loss prevention, while
promoting accessibility and affordability of care (e.g., Choi
et al., 2009).
Audiologic Monitoring of Patients with cCMV Positive
Outcomes
Before cCMV testing was implemented (see Figure 2),
the audiologists worked to define a protocol for monitoring
the newborns who test positive for cCMV. The defined
protocol (see Figure 4), described earlier is similar in
approach for those who have a higher degree of suspicion
for or are known to have hearing loss as it is for those
who continue to have results suggesting hearing that is
within normal limits. The main difference is a focus on
streamlined screening using more objective measures for
those who continue to exhibit typical hearing in the context
of a larger diagnostic assessment and monitoring plan as
appropriate (e.g., Foulon et al., 2015; Park et al., 2014).
There are ongoing multi-site studies from leading research
centers in this realm (e.g., Choi et al., 2009; 2013; Haller
et al., 2020; Park et al., 2014) validating various types of
testing for cCMV and looking at the efficacy of treatment
on hearing loss prevention. Findings from these continued
efforts will be key for informing future changes in clinical
practices and prioritizing global efforts for early detection
and monitoring of hearing loss across the life span (e.g.,
JCIH, 2019; WHO, 2021).
Lessons Learned and Future Considerations
There are several aspects to consider when testing for
cCMV, from the perspectives of the patient and their family
as well as the interprofessional care teams in relation to
hearing monitoring. Several of these considerations were
gathered as part of the development of this clinical practice
initiative and represent several areas needing further and
larger scale exploration. Here we highlight considerations
for social, clinical practice, and longer-term/life-span care
approach.
Social considerations may include such items as the
patient’s birth hospital may not be their managing
hospital, requiring internal and external care pathways
to be clearly defined. Patient and family ability to return
for frequent monitoring (e.g., travel/financial burden)
may also be a factor to address for the clinical program.
Patient education materials may be overwhelming or
not specific to the needs of the individual. Moreover,
variability may exist in expected outcomes based
on elected treatment and management options.
Affordability and accessibility of care also warrants future
consideration.
Clinical practice considerations may include the fact that
infectious disease treatment options for symptomatic
cCMV symptoms require close monitoring and may
have varied outcomes. The individualized treatment
approach supported through the interprofessional
collaborative care team is deemed to be important for
this and warrants future investigation. The complexity of
audiologic evaluation in young children as well as in those
who are neurologically complex is also a consideration

given screening tool limitations and balancing affordability
of preventative monitoring. There may be limitations
to appointment availability and coordinating between
audiology and associated sub-specialties (e.g., Pediatric
Infectious Disease, Genetics, Pediatric Otolaryngology,
etc.). The timeline for cCMV testing and confirming hearing
status is short to maximize treatment and management
options. Until cCMV testing is universal, allowing
early intervention for sensorineural hearing loss and
developmental delay where appropriate (Rawlinson et al.,
2017), current workflows require ordering of the test and
this can increase the risk of missed tests.
Considerations across the lifespan and long-term for
meeting the needs of the patient are worth immediate
consideration as well as continued refinement as evidence
emerges. Long term audiologic monitoring is recommended
for those identified with cCMV regardless of newborn
hearing screening outcome given potential risk for later
onset hearing loss. The details of how often and what
tools are rapidly emerging with increasing exploration as
balancing accessibility, affordability, and quality of care
continues to be weighed. It is our recommendation that
clinical care pathways should be tailored to the individual
needs of the patient and based on treatment options elected.
Conclusion
Although cCMV is the leading non-genetic cause of
childhood hearing loss in the United States, there are
not widespread established practices for cCMV testing
universally at birth or on babies who refer on newborn
hearing screening. Development of this interprofessional
quality improvement project has greatly enhanced
Mayo Clinic protocols and care plans for working
with patients with cCMV and their families. It has also
enhanced our ability to make recommendations for
patients later identified with CMV. It has strengthened
the interprofessional collaborative care relationships that
audiology has with primary care and various specialties.
Although this targeted screening project has identified
fewer patients testing positive for cCMV than anticipated,
it could be expected that the implementation of a program
such as this could have positive implications for practices
that have the resources to manage necessary referrals
and follow up. Moreover, until cCMV testing is universal,
clinical protocols need to account for the complexities of
individualized care in partnership with interprofessional
care team coordination.
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